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Public Health, Fudan University, Shanghai, ChinaA B S T R A C TObjective: The purpose of this guidance was to assist in the adapta-
tion of pharmacoeconomic models originally developed in one coun-
try and intended for use in another. The intent was to produce
user-friendly recommendations and a checklist for adapting a global
model to treat a speciﬁc disease state. This guidance will allow model
developers to tailor existing models so that they are “locally appli-
cable,” while maintaining the scientiﬁc integrity of the original
pharmacoeconomic model and will beneﬁt formulary decision makers
and other stakeholders involved in evaluating pharmacoeconomic
studies. Methods: A working group of experts from various countries
participated in the Global Pharmacoeconomic Model Guidance devel-
opment to discuss the adaptation of pharmacoeconomic models.
A systematic review of studies adapting pharmacoeconomic models
and translation across countries was conducted and recommenda-
tions were made for adaptation. The working group interviewed
internal and external stakeholders to solicit best practices for model
adaptation and developed a draft set of key principles and generalee front matter Copyright & 2014, International S
r Inc.
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Street, 12th Floor, Baltimore, MD 21201.recommendations for global adaptation. Results: The working group
provided a set of 16 recommendations for adapting pharmacoeco-
nomic models for local decision makers. The recommendations span
various aspects of estimating or modeling both the costs and effec-
tiveness of pharmacoeconomic models as well as guidance for
ensuring local acceptability. Conclusions: These recommendations
and the related principles not only will provide pharmacoeconomic
models that are meaningful to local decision makers but also will
improve the consistency and credibility of pharmacoeconomic model
adaptations. The guidance may also help those who will build the
original models to design them with the ﬂexibility to allow pharma-
coeconomic model adaptations as described in this document.
Keywords: cost-effectiveness analysis, health technology assessment,
pharmacoeconomic model.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Economic modeling is widely used in economic evaluation of
pharmaceuticals (cost-effectiveness analysis, cost-utility analysis,
cost-beneﬁt analysis, and budget impact analysis) to evaluate the
health care costs and health outcomes of alternative courses of
action in the presence of scarce resources in terms of both their
cost and consequences. A number of countries faced with increas-
ing pressure to make use of health care resources use economic
evaluations to guide their reimbursement of pharmaceuticals [1,2].
For example, Latin America and Caribbean stakeholders need to
adapt existing pharmacoeconomic models for the local region.
They need to consider coverage and reimbursement, as well as
clinical decision making. These stakeholders prefer to adapt health
technology assessment reports from Europe, the United States,Canada, and Australia because of the applicability of the descrip-
tion, as well as the safety and effectiveness of the technology [3].
The adaptation of a pharmacoeconomic model across different
countries to support region-speciﬁc economic evaluation of phar-
maceuticals requires the originally developed model to structurally
adapt to the economic and clinical characteristics of the intended
country. Ensuring the reliability (i.e., reproducibility) of measure-
ments across different geographical regions requires comparing
and/or adjusting data from clinical trials, observational studies,
claims databases, case registries, public health statistics, and
surveys to estimate the economic impact of the uptake and use
of a particular pharmaceutical in the intended country of interest.
The concept of “pharmacoeconomic model adaptation” raises
the issue of “transferability” across geographical regions. The trans-
ferability of pharmacoeconomic models refers to the adaptation ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ical regions [4]. The transferability of economic evaluation results
requires the use of a general “knockout criteria” to determine
whether the model can be transferred to the decision country [2].
To ensure the reliability of the pharmacoeconomic model, the
analyst must then determine which part(s) of the model needs to
be adapted to reproduce the model in a different geographic region.
To determine which parts of the model need adaptation, there are
several transferability factors to consider.
The factors that create challenges for developing a model for
adaptation include differences in the epidemiology of the disease,
mortality rates, disease severity, demographic characteristics, risk
factors, available treatment options, discount rates, absolute or
relative prices, and differences in practice patterns [5–8]. These
factors can be broadly grouped into methodological, health care
system, and population characteristics [7]. The transferability of
the above factors or of the entire pharmacoeconomic model will
depend on the type of economic modeling, data availability, and
the need for modeling-based adjustments. For example, if the goal
of the pharmacoeconomic model is to measure the economic
burden of a disease or diseases on a particular society in monetary
terms, it is important that costs and effects accruing in future years
be discounted to their present value using widely accepted rates
because the time horizon for therapies in certain conditions is long
[5,9]. This is especially true for chronic diseases—such as heart
disease, cancer, and diabetes—in which the course of the disease is
persistent or long-lasting in nature. However, because the perspec-
tive of the decision maker is usually the societal perspective for
resource allocation decisions, the choice of a discount rate for
economic evaluation may not reﬂect the societal preference for the
intended country. When there is variability in the discount rate,
the appropriate societal discount rate should be chosen on the
basis of the perspective of the analysis and on some theoretical
approach, especially when the analytic result is sensitive to the
discount rate [6]. Although the choice of the discount rate is an
important topic in the context of health economic evaluations, we
must also underscore the importance of relative prices.
It is recommended that pharmacoeconomic models include all
relevant direct health care costs in the evaluation, including indirect
costs when appropriate, which will depend on the aim of the study,
treatment comparator, the perspective of the evaluation, and the
guidelines of the jurisdiction [10]. Unit cost prices of pharmaceut-
icals and/or medical services should be from the jurisdiction of
interest, but due to possible differences in relative or absolute prices,
the data on resource use may need to be adapted to the jurisdiction
of interest [3]. Currently, there is no consistent guidance on how to
address the transferability of economic data for evaluation or on
how to adjust for such differences in prices between jurisdictions
[3,11]. Addressing the differences in relative prices is very important
for determining what happens to the transfer of economic data
from one country to another because these differences can lead to
different interpretations of cost-effectiveness data in the jurisdiction
of interest, especially if there are substantial differences in relative
prices [3,11,12]. The comparison of prices across jurisdictions has
been the subject of careful investigation of whether markets are
truly integrated [13], a term used to describe how much different
markets are to each other. There is evidence to suggest that
countries/jurisdictions within geographic proximity, similar health
care structure, and/or similar political economy will likely have cost-
effectiveness results that are generalizable [10,14,15]. This idea of
prices of similar products to be equal across countries is especially
true for countries within the European Monetary System, which
operate under a uniﬁed currency, the euro. The use of purchasing-
power-parity exchange rates or market exchange rates in economic
modeling may be necessary when there exist some widely varying
price structures between countries; the latter is likely to provide
inaccurate estimates of relative incomes and outputs [16].Difference in medical practice patterns across geographic
regions is another important factor to consider when transferring
cost-effectiveness data to another jurisdiction. These differences
in medical practice between countries would produce differences
in resource input, utilization of services, and expenditure among
neighboring jurisdictions [17]. Therefore, practice variations
between countries/jurisdictions are likely to cause uncertainty
in the apparent effectiveness of the health service and thereby
make the transferability of cost-effectiveness estimates from one
country to another impractical unless adjustments can be made
[11,18]. Adjustments for differences in medical consumption on
relatively homogenous groups can be done by correcting for the
difference either upward or downward [11].
In determining the transferability of clinical and economic data,
pharmacoeconomic models must also address another important
factor known as the case mix. A case mix is composed of subgroups
of patients possessing similar demographic characteristics, clinical
attributes, and output utilization patterns [19]. A case mix–based
payment system assumes that within diagnosis-related groups
there is little variability in clinical attributes and processes of care;
therefore, the cost-effectiveness results can be transferable across
jurisdictions with similar case mix. Case-mix differences can
account for higher medical cost [20], differences in medical treat-
ment practices [21], and variations in treatment outcomes [22] in
certain jurisdictions. Variation in treatment outcome is termed
“heterogeneity of treatment effects” and identifying potential
heterogeneity of treatment effects is necessary to aid in the design
of pharmacoeconomic model for adaptation. The type or mix of
patients treated may vary substantially between countries, which
can affect the cost-effectiveness of an intervention. Therefore, if
the heterogeneity of treatment effects in certain jurisdictions is
likely, then the use of statistical methods may be needed to adjust
for observed differences, and thus allow for more (less) speciﬁc
therapeutic recommendations in the jurisdiction of interest [23–26].
Methods
A working group was convened consisting of experts from various
countries who participated in a Global Pharmacoeconomic Model
Guidance development to discuss the adaptation of pharmacoeco-
nomic models, originally developed in one country for use in
another country. A review of studies adapting pharmacoeconomic
models and translation across countries was conducted. The work-
ing group discussed controversies surrounding “translation” across
countries and recommendations to consider for adaptation. Before
preparing the draft report, the working group interviewed internal
and external stakeholders responsible for conducting modeling
studies to solicit best practices for model adaptation. The Global
Pharmacoeconomic Model Guidance working group developed a
draft set of key principles and general recommendations for global
adaptation. The working group met by phone 4 times and used a
Delphi approach via e-mail to obtain consensus on the ﬁnal set of
recommendations. Each working group member was also asked to
obtain input from two or three additional experts from his or her
region. Based on solicited feedback on these draft recommenda-
tions, a set of ﬁnal recommendations and corresponding rationale
was developed.Results
The research results described in this guidance deﬁne acceptable
standards and explains best practices for the transferability of
economic and clinical data before submitting an economic evalu-
ation for reimbursement. It takes into account the accepted
hierarchies in the levels of evidence (see Fig. 1) and also provides
pragmatic recommendations. A checklist (see Fig. 2) is provided at
Levels of Evidence for Pharmacoeconomic Decision making
Higher
Strength of Evidence
Lower
Sources of Eﬃcacy Data Sources of Cost Data
1.Clinical trials 1. Naonal esmates
2. Observaonal studies 2. Regional/local esmates
3. Insurance databases 3. Single or group of hospitals or
instuons
4. Case registries 4. Esmates from similar 
geographical regions 
5. Public health stascs 5. Expert opinion
6. Surveys
7. Unpublished data
Fig. 1 – Levels of evidence for efﬁcacy/effectiveness and cost data.
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coeconomic model adaptions.
Recommendation 1: When adapting a pharmacoeconomic
model for local decision makers, follow recommendations for
good research practices for conducting pharmacoeconomic stud-
ies and pharmacoeconomic modeling, such as those provided
by ISPOR.
Rationale: Local adaptation of a pharmacoeconomic model
assumes that the original model is methodologically sound.
Otherwise, the adaptation will retain the same ﬂaws that were
inherent in the original pharmacoeconomic model.
Implementation: Before adapting a model, the original model
should be vetted by at least three experts for structure and
scientiﬁc integrity if that was not done during the original
pharmacoeconomic model development process.
Recommendation 2: Familiarize yourself with national, regional,
local, or individual payer or technology appraisal agency phar-
macoeconomic guidelines and use recommendations and sug-
gested best practices when adapting a global model for individual
payer decision makers.
Rationale: National or local pharmacoeconomic guidelines
developed by jurisdictional experts reﬂect the best judgment on
pharmacoeconomic practices and strategies of pharmacoeconom-
ics in the context of their jurisdiction. Many of these guidelines are
consensus documents developed by multiple stakeholders and
experts working within the country even if they are not ofﬁcially
endorsed by a government entity. After extensive research and
evaluation, the opinion leaders in the country propose their expert
opinion on the most effective pharmacoeconomic practices for the
country, and such experts often inﬂuence the appraisal or cover-
age decision processes. Thus, such guidelines should be followed
when they exist, even when they are in conﬂict with other
recommendations contained in this guidance. A sensitivity anal-
ysis, however, may be warranted to reﬂect the recommendations
contained herein to provide scientiﬁc validity and because guid-
ance documents may evolve over time.
Implementation: Before submitting an economic evaluation for
reimbursement, determine whether there are guidelines that
represent a consensus view among economists and experts in
the intended country of interest. If no such guidance exists,
consider regional guidelines and/or recruiting a local expert and/
or key opinion leader from the region to review the adaptation
process and resulting pharmacoeconomic model to ensure cred-
ibility and applicability.Recommendation 3: Determine the perspective of the adapta-
tion, which may be a societal national payer, a regional payer, or
an institutional perspective. The perspective will determine other
aspects of pharmacoeconomic model adaptation.
Rationale: The societal perspective is commonly used in cost-
effectiveness analysis, but the choice of the study perspective
should consider the decision maker regarding the use of new
technologies in a particular country.
Implementation: In the absence of speciﬁc guidance from the
local decision maker, provide both the societal perspective and a
narrow focus on direct medical costs only. If desirable, also
include an intermediate perspective (e.g., direct medical costs
and productivity costs).
Recommendation 4: Select the comparators that reﬂect the
current treatments and treatment algorithms (e.g., dose and
duration) that are most likely to be replaced by the new therapy.
Rationale: The choice of the appropriate comparator is very
critical because the cost-effectiveness of an intervention is a
relative measure of the cost and effectiveness of any alternative,
which is dependent on the choice of the comparator.
Implementation: The choice of the comparator must be appro-
priate to the research question and should reﬂect current practice
or the most widely used therapy/therapies in the jurisdiction of
interest. Occasionally, current practice may differ by jurisdiction,
so the payer or decision maker in the jurisdiction of interest may
specify which alternatives should be compared.
Recommendation 5: Always use cost data from the speciﬁc
country. When various data sources exist, the following data
hierarchy should guide which data source is most reliable and
applicable for pharmacoeconomic model adaptations for cost or
resource utilization estimation: 1) national estimates, 2) regional/
local estimates, 3) single or group of hospitals or institutions, and
4) expert opinion.
Rationale: The geographical separations of markets, differences
in clinical practice patterns, different payment systems, and
various incentives from drug manufacturers are some of the
various factors identiﬁed as preventing prices of similar products
to be equal across countries or variability in resource use between
locations. The international markets are not as integrated as
domestic markets, so it is important that national estimates data
for resource consumption be considered ﬁrst.
Implementation: If cost data from the speciﬁc country are
not available, apply a standard cost per procedure across all
participating sites to derive a dollar value for costs of care.
No. Recommendation Implementation Yes No
1 Conduct good
research practice for
Pharmacoeconomic
studies  
The original model should be vetted for structure
and scientific integrity.  
2 Use recommended
economic appraisal
guidelines and
required reporting and
appraisal standards    
Refer to recommended economic appraisal
guidelines.  If no such guidance exists, consider
recruiting a local expert and/or key opinion leader
from the region to assure credibility and
applicability.    
3 Determine perspective
of economic appraisal 
In the absence of specific guidance from local
decision maker, use both the societal perspective
and a narrow focus on direct medical costs only. If
desirable, include intermediate perspective.   
4 Select available
treatment options
(comparators)  
Use current practice or the most widely used
therapy/therapies in the jurisdiction of interest. 
5 Consider the source of
cost data 
If cost data from the specific country is not
available, apply a standard cost per procedure.  
6 Identify and quantify
resource use and
costs  
Include relevant direct and indirect costs associated
with the treatment. An activity-based costing
method can generate a more accurate product 
costs.  
7 Consider clinical
practice patterns and
guidelines  
When using decision analytic modeling, incorporate
clinical practice patterns/guidelines of the intended
country/jurisdiction of interest.  
8 Use country/region
specific epidemiologic
data  
If country/region specific epidemiologic data are not
available, use random-effect meta-analysis models
and transition probabilities where necessary.  
9 Explain and justify use
of estimated treatment 
effect 
Use the average treatment effect from a
multinational trial. Conduct a sensitivity analysis
using treatment effect based upon patients from the
specific country or region.  
 10 Use health state
preferences/utilities
that are applicable to
the region   
Use local health state preferences and utilities
whenever they are available; Use the average of
published ones if local utilities are not available. If a
revalidation is required/desired, include forward
translation, back translation, and pretesting of the
instrument.     
11 Utilize expert opinion
sparingly and
appropriately   
Expert opinion represents lower levels of evidence.
Whenever expert opinion is used, multiple experts
should be involved. Use the Delphi method for
consensus.  
12 Use modeling to
address
nontransferable
elements    
For data elements that are nontransferable, the
model structure, data used as inputs to 
models, and model validation are important when
assessing the quality of models. See
http://www.ispor.org/taskforces/GRPModelingTf.asp
for more information.     
13 Utilize quality-adjusted
life years(QALYs) 
Determine threshold to enable transfer and
applicability of QALYs across jurisdictions unless
local guidelines recommend a different metric or
approach.   
14 Determine and justify
discount rate 
Use local guidance for discount rate.  If none exist,
use a “real riskless” discount rate of 3% and
conduct sensitivity analysis.  
15 Source and
justification of each
data element in PE
model   
To reflect an evidence-based approach to PE
modeling, systematic reviews of the literature
should be conducted.  
16 Translate findings for
the desired perspective  
The perspective, the recommendations concerning
evaluation of resource use/costs, the choice of the
comparator, and the valuation of costs should be
considered before considering the transferability
and reproducibility.    
Fig. 2 – Checklist of pharmacoeconomic model adaptation strategies: A tool for decision making.
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involved and ideally a Delphi process should be used to achieve
consensus.Recommendation 6: Cost data should include direct medical
costs as well as other components of costs (e.g., lost productivity
and overhead costs) when available from the speciﬁc country.
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able to determine where the components come from and which
costs are the major drivers.
Rationale: Many factors affect medical care costs, and the
disaggregation of cost into individual cost drivers can uncover
the major source of variation in medical care costs from one
jurisdiction/region from another.
Implementation: In cost estimation procedures, assigning cost
to cost out products may require including other components of
costs on a cause-and-effect-basis. An activity-based costing
method with multiple cost pools, activity drivers, and allocation
bases can generate more accurate product costs.
Recommendation 7: Incorporate clinical practice patterns that
reﬂect how the disease or condition is treated within the juris-
diction. In doing so, be sure to address whether treatment occurs
at a hospital, an outpatient clinic, or a physician ofﬁce. Also
address the number and types of drugs, other health technologies,
and services received, including whether general practitioners
and/or specialist physicians are involved in treatment.
Rationale: Differences in medical practice patterns between coun-
tries can produce differences in resource input, utilization of services,
and expenditure among neighboring jurisdictions, thereby causing
uncertainty in the apparent cost-effectiveness of the health service.
Implementation: Understand and incorporate the patterns of
clinical practice or clinical guidelines in the intended country/
jurisdiction of interest when using statistical techniques such as
Markov analysis, decision trees, and discrete event simulation to
extrapolate results from one jurisdiction to another.
Recommendation 8: Use country-speciﬁc incidence or preva-
lence and other local epidemiologic data (e.g., clinical parame-
ters, mortality, morbidity, and comorbidity) and transition
probabilities when adapting a pharmacoeconomic model, even
if treatment patterns are similar to the practice of medicine in the
original model’s country.
Rationale: Even if the baseline risk of disease is the same across
countries, the progression of disease could differ, so local tran-
sition probabilities between health states may differ from those
within the original pharmacoeconomic model.
Implementation: Use Markov transition models to model dis-
ease progression. Transition probabilities should reﬂect the
current health state of persons in the intended country of interest
and not the health states of those in the original model.
If country-speciﬁc incidence or prevalence rates and other local
epidemiologic data are not available, use random-effect meta-
analysis models to combine the evidence data and then convert
into transition probabilities if necessary; in such instances,
sensitivity analysis is recommended.
Recommendation 9: In contrast to other aspects of a pharma-
coeconomic model, the treatment effect generally is highly trans-
ferable and, therefore, often does not need to be altered during
country adaptation. Therefore, if adaptations are made, justify
why the treatment effect is tailored and provide a valid source for
the local data on the effect of treatment.
Rationale: Unlike estimates of baseline risk, estimates of treat-
ment effect are generally considered to have high transferability
when there is little to no difference in patient characteristics,
comparators, and treatment practice patterns.
Implementation: In addition to using the average treatment
effect from a multinational trial, the treatment effect based on
patients from the speciﬁc country or region should be provided
as sensitivity analysis unless the sample size is extremely small.
Recommendation 10: Health state preferences/utilities are not
transferable; therefore, a study-speciﬁc evaluation is needed to
obtain local values for such data elements. Unless such estimates
are obtained through a valid patient-reported outcome (PRO) instru-
ment (including linguistic validation), it is preferable to use a
published or otherwise validated estimate from another jurisdiction.Rationale: Health state utilities quantify an individual’s pref-
erences for different health outcomes and so the use of an
existing validated PRO instrument does not necessarily enable
the transfer of preferences/utilities across different countries/
jurisdictions to predict preferences associated with actual expe-
rienced health states. Therefore, to reﬂect a more valid prefer-
ence associated with an experienced health state in the country/
jurisdiction of interest, translation and cultural adaptation of
existing instrument is recommended. The average of published
utilities, however, can be used if local utilities are not available.
Implementation: Use local health state preferences and utilities
whenever they are available; however, if local utilities are not
available, use the average of published ones along with sensitiv-
ity analysis. If a revalidation of a PRO is required/desired, the
process should include forward translation, back translation, and
pretesting of the instrument to assess the PRO.
Recommendation 11: Country-speciﬁc data are generally pre-
ferred over local expert opinion when available. The balance
between country-speciﬁc data and expert opinion is a spectrum.
The more data that are available, the less expert opinion is
necessary, while a lack of data must be supplemented with
expert opinion. Expert opinion should be used to evaluate the
quality of the data and the ability for it to be transferred to the
speciﬁc country.
Rationale: Clinical decision making and recommendations
based on expert opinion represent lower levels of evidence,
indicating little to no objective empirical evidence.
Implementation: As stated in Recommendation 5, whenever
expert opinion is used, multiple experts should be involved and
ideally a Delphi process should be used to achieve consensus.
Recommendation 12: Modeling can be used when key data
elements are found to be nontransferable and should incorporate
the demographic characteristics of the local jurisdiction.
Rationale: If the cost-effectiveness results of a treatment are
not easily transferable from location to location, then random-
effects meta-analysis models may be used to pool estimates and
some form of formal modeling approach is needed.
Implementation: ISPOR and the Society for Medical Decision
Making had a Joint Modeling Good Research Practices Task Force.
The current draft of the series of reports is available online at
http://www.ispor.org/taskforces/GRPModelingTf.asp.
Recommendation 13: Despite concerns about the estimation and
transferability of utilities, quality-adjusted life-years (QALYs)
remain an accepted “second best” metric and should be used as
a primary output of pharmacoeconomic models across jurisdic-
tions unless local guidelines recommend a different metric or
approach.
Rationale: Population values and preferences could vary, but
the QALY metric represents a generic outcome measure that can
be applied more generally.
Implementation: The transfer and applicability of QALYs across
jurisdictions will be largely driven by the threshold value for the
QALY, the use of an utility instrument that ensures that concepts
within an instrument are equal between original and target
jurisdiction (language, time, and context), and the appropriate-
ness of the instrument for assessing utility.
Recommendation 14: Use a discount factor that reﬂects the
appropriate discount rate for the local jurisdiction.
Rationale: The perspective of the decision maker is usually the
societal perspective for resource allocation decisions. The choice
of a discount rate for economic evaluations should reﬂect the
societal preference for the intended country because an analytic
result can be sensitive to the discount rate.
Implementation: If there is local guidance for a speciﬁc discount
rate, use that rate. If there is no local guidance, use a “real
riskless” discount rate of 3% and sensitivity analysis using 5% as
well as a reasonable range of discount rates (e.g., 0%–10%).
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data element or assumption that is included in the adaptation so
that the pharmacoeconomic model adaptation clearly reﬂects an
evidence-based approach to pharmacoeconomic modeling; also,
justify why parameters that are kept from the original model are
not changed.
Rationale: The transparency of methods and justiﬁcation of key
parameters in the model will not only ensure transferability and
reproducibility of results but would also inﬂuence the allocation
of health resources by decision makers.
Implementation: Conduct a systematic literature review to
provide inputs for the economic model. Regularly, sources such
as “previous unpublished study” or “presentation on a local
conference” are used to retrieve input data. In particular in small
countries with missing national literature sources, such inputs
may be inherited for years.
Recommendation 16: Provide a translation of ﬁndings that
addresses the perspective of the local decision maker so that
results are believable and meaningful.
Rationale: The guidelines for health economic evaluations
generally point out that the perspective should be the societal
perspective. The choice of the analytical aspects of the study
should be within the scope of the perspective.
Implementation: Guidelines for health economic evaluations may
vary between jurisdictions and so the perspective of the evaluation,
the recommendations concerning the evaluation of resource use/
costs, the choice of the appropriate treatment comparator, and the
valuation of costs should be considered before considering the
transferability and reproducibility of the study results.Conclusions
The following key guiding principles should be kept in mind to
guide pharmacoeconomic model adaptations across geographic
jurisdictions.
Principle 1: Before developing a local adaptation of a model, the
model and availability of data should be evaluated using general
knockout criteria or a checklist of critical transferability factors. A
minimum standard of quality must be met before the local
adaptation can even be considered for transferability [7,27].
Principle 2: Throughout this document, the term “local” juris-
diction is used to describe the jurisdiction or institution for
which a pharmacoeconomic model is being adapted and, as
such, could reﬂect a country, a region within a country, a
speciﬁc national, regional, or local payer, a single institution,
or a group of institutions. Assess the variability of the factors
that can potentially affect the transferability of data from one
“local” jurisdiction to another and perform probabilistic or
multivariate sensitivity analysis [8,11,28,29].
Principle 3: Transferability is a spectrum, with “fully trans-
ferable” data describing a model that is completely trans-
ferable across a group of countries or jurisdictions with
similar health care environments and pharmacoeconomic
practices. “Nontransferable” describes a situation in which
there is a critical failure that makes the entire model non-
transferable either because of the model structure or data
availability in the local jurisdiction. Within a study deemed to
be transferable, each data element also exists on a spectrum
of transferability [6,8,30].
Principle 4: A well-constructed model that is designed with
adaptation in mind often is transferable across a wide area of
countries. Frequently, the problem with adaptation is not so
much the structure of the model so much as the lack of data
availability for the adaptation process. The model structure is
more problematic when speciﬁc comparators or componentsof treatment are “hardwired” into the model structure; when
that is the case, the model cannot be adapted to local decision
makers for whom the comparator treatments or aspects of
care do not apply [14,31].
Principle 5: Following the decision on whether part(s) or the
wholemodel is deemed to be transferable, transparency ofmodel
assumptions, characteristics, and limitations for data elements
that are considered transferable will allow economic evaluations
to be more informative for the intended user in the decision-
making process [10,32].
Principle 6: Before adaptation, the individual(s) who is respon-
sible for tailoring the model must be trained on the model,
ideally by the developer of the original model. This ensures
that the local adaptation maintains the general structure and
key components and properties of the pharmacoeconomic
model [22,33].
Principle 7: Local adaptation is best informed with input from
local decision makers or their proxies/surrogates in advance of
model adaptation [34–36].
Principle 8: Countries differ in terms of whether they view
pharmacoeconomic models to be transferable from countries
that are either within their geographic proximity and/or have
a similar health care structure. Political, social, and economic
factors also affect whether a pharmacoeconomic model is
transferable across jurisdictions. Before pooling data, the
transferability between jurisdictions should be viewed as
acceptable by the intended user of the pharmacoeconomic
model. For example, transferability is viewed as reasonably
acceptable among countries in Latin and South America that
have similar size and economies and generally not acceptable
among Asian countries. In Europe, transferability of effective-
ness parameters is acceptable across Western and parts of
Eastern Europe, whereas costs are not [21,37,38].
Principle 9: Countries that have limited experience with phar-
macoeconomic evaluation and limited data availability are
more likely to deem economic evaluations and data elements
to be transferable. They also, however, are more likely to focus
on affordability and so the pharmacoeconomic model may be
less impactful than a budget impact model [24,39].
Principle 10: Despite advances in the use of pharmacoeconomic
models and improvements in pharmacoeconomic modeling and
adaptation, there is continued need for knowledge dissemination
and efforts to increase awareness of local decisionmakers, which
may include education of clinicians as well as policymakers
because clinicians affect the policymakers’ decisions [24,40,41].Source of ﬁnancial support: This work was supported by
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